A tool called “polygenic risk scoring” could help physicians identify who faces a high risk of serious diseases.

Brand-new U.K. biotech Izana has kicked off a phase 2a trial of anti-GM-CSF antibody namilumab in ankylosing spondylitis.

Mustang Bio is expanding its pipeline beyond CAR-T cancer treatments by licensing a gene therapy from St. Jude Children's Research Hospital.

MD Anderson and Accelerator Life Science Partners unveiled Magnolia Neurosciences, to develop neuroprotective drugs with a $31 million series A.

Japan’s Astellas Pharma has delved deeper into the gene therapy sector, picking up U.K. specialist Quethera for around $109 million.

A Yale University team found two potential methods for preventing fat particles from slipping into tissues.

DNAlite Therapeutics gathered $1.5 million in seed money for gene therapies that slip through the mucus typically blocking access to the GI tract.

In our EuroBiotech roundup this week, Bavarian Nordic posts RSV vaccine data, ADC starts a phase 2 trial and Silence shares a patent dispute update.